Division of Allergy, Immunology and Rheumatology, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY, 14642, USA.
Rochester General Hospital Research Institute, 1425 Portland Avenue, Rochester, NY, 14621, USA.
Am J Clin Dermatol. 2018 Feb;19(1):119-126. doi: 10.1007/s40257-017-0312-y.
Alopecia areata (AA) is an autoimmune disease characterized by non-scarring alopecia with T-cell infiltration at the affected hair follicle.
Our aim was to study the potential link between hepatitis B virus (HBV) antigen exposure and AA.
Two pediatric patients with AA following hepatitis B vaccination were identified in a general dermatology clinic. A bioinformatics analysis and an electronic medical record (EMR) database query were performed at the University of Rochester Medical Center to identify patients with AA, coexisting viral infections, vaccinations, or interferon (IFN) therapy in order to determine if the presence of AA and these conditions was higher than in AA patients without these associated conditions or therapy.
An increased frequency of AA among those who received the HBV surface protein antigen [odds ratio (OR) 2.7, p < 0.0001] was identified, and an independent analysis revealed an increased frequency of AA in those receiving IFN-β treatment (OR 8.1, p < 0.05). One potential antigenic target identified was SLC45A2, a melanosomal transport protein important in skin and hair pigmentation. The longest potential vaccine peptide fragment match (8-mer) was to a segment of natural killer (NK) cell inhibitory receptors, KIR3DL2 and KIR3DL1. Predictive modeling of major histocompatibility complex (MHC)-peptide binding demonstrated potential binding of this peptide to MHC relevant to AA.
The results will need to be verified in additional patient databases allowing analysis of temporal relationships, and with molecular experiments of the identified antigens.
Our data confirm associations between viral infection and IFN treatment with AA. It establishes that the hepatitis B surface protein antigen has shared epitopes with human killer immunoglobulin-like receptors.
斑秃(AA)是一种自身免疫性疾病,其特征是在受影响的毛囊处出现 T 细胞浸润的非瘢痕性脱发。
我们旨在研究乙型肝炎病毒(HBV)抗原暴露与 AA 之间的潜在联系。
在一家普通皮肤科诊所发现了两名接种乙型肝炎疫苗后出现 AA 的儿科患者。罗切斯特大学医学中心进行了生物信息学分析和电子病历(EMR)数据库查询,以确定 AA 患者、合并病毒感染、疫苗接种或干扰素(IFN)治疗的患者,以确定 AA 患者和这些情况的存在是否高于无这些相关情况或治疗的 AA 患者。
发现接受 HBV 表面蛋白抗原的人群中 AA 发生的频率增加(优势比[OR]2.7,p<0.0001),独立分析显示接受 IFN-β治疗的人群中 AA 发生的频率增加(OR 8.1,p<0.05)。鉴定出的一个潜在抗原靶标是 SLC45A2,这是一种在皮肤和毛发色素沉着中起重要作用的黑素体转运蛋白。最长的潜在疫苗肽段匹配(8 -mer)是天然杀伤(NK)细胞抑制受体 KIR3DL2 和 KIR3DL1 的一段。主要组织相容性复合物(MHC)-肽结合的预测模型表明,该肽与与 AA 相关的 MHC 具有潜在的结合能力。
需要在允许分析时间关系的额外患者数据库中验证这些结果,并进行鉴定抗原的分子实验。
我们的数据证实了病毒感染和 IFN 治疗与 AA 之间的关联。它确定了乙型肝炎表面蛋白抗原与人杀伤免疫球蛋白样受体具有共同表位。